COVID-19 Vaccine Acceptance Among Parents of Children With Multisystem Inflammatory Syndrome in Children

• Published in: The Pediatric infectious disease journal Vol. 43; no. 4; pp. 361 - 364
• Main Authors: Blanchard-Rohner, Geraldine, Sanchez, Carlos, Andre, Maya C, Bressieux-Degueldre, Sabrina, Grazioli, Serge, Perez, Marie-Helene, Wütz, Daniela, Schöbi, Nina, Welzel, Tatjana, Atkinson, Andrew, Schlapbach, Luregn J, Bielicki, Julia A, Trück, Johannes
• Format: Journal Article
• Language: English
• Published: United States Lippincott Williams & Wilkins 01-04-2024
• Subjects: COVID Reports
• ISSN: 0891-3668; 1532-0987
• DOI: 10.1097/INF.0000000000004206

Data on COVID-19 vaccine acceptability among parents of children with multisystem inflammatory syndrome (MIS-C) are limited. In this cohort of children with MIS-C, enrolled in the Swissped RECOVERY trial (NCT04826588), comparing intravenous immunoglobulins or methylprednisolone, who, in accordance with Swiss guidelines, were recommended for SARS-CoV-2 vaccination, 65% (73/112) of parents reported being vaccinated against SARS-CoV-2 before the MIS-C, while 70% were vaccinated after the MIS-C episode of their child. None of the children were vaccinated before the occurrence of the MIS-C, and only 9% (5/56) received the COVID-19 vaccine after the MIS-C. The predominant barriers to COVID-19 vaccination were concerns over potential side effects and insufficient support from their doctors. This emphasizes the crucial role of health care providers in promoting COVID-19 vaccination among children.